The Austral University Hospital is a teaching hospital in Argentina. It provides hospital care, teaching, and medical research. It is part of the Austral University Academic Center of Health, along with the School of Biomedical Sciences.

During the past decade, Hospital Universitario Austral conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 21 clinical trials were completed, i.e. on average, 51.2% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 16 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario Austral" #1 sponsor was "Janssen Research & Development, LLC" with 5 trials, followed by "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials sponsored, "Alexion" with 2 trials sponsored, "Allergan" with 2 trials sponsored and "Amicus Therapeutics" with 2 trials sponsored. Other sponsors include 40 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario Austral" #1 collaborator was "Canadian Cancer Society (CCS)" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Cystic Fibrosis Foundation" with 1 trials as a collaborator, "Cytel Inc." with 1 trials as a collaborator and "ECFS-Clinical Trial Network (ECFS-CTN)" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario Austral" are "Chronic Hepatitis" (2 trials), "Cystic Fibrosis" (2 trials), "Dermatitis, Atopic" (2 trials), "Genetic Diseases, Inborn" (2 trials) and "Hepatitis B" (2 trials). Many other conditions were trialed in "Hospital Universitario Austral" in a lesser frequency.

Most popular intervention types in "Hospital Universitario Austral" are "Drug" (41 trials), "Other" (10 trials), "Biological" (5 trials), "Device" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "AT2221" (2 trials), "ATB200" (2 trials), "Adefovir" (2 trials) and "Clevudine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario Austral" are 53 trials for "All" genders, 3 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Universitario Austral". undefined are not yet recruiting, 9 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Hospital Universitario Austral, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario Austral, 3 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".